En español
NIDA

Menu

Suboxone® (Buprenorphine/Naloxone) Taper: A Comparison of Two Schedules

Suboxone Buprenorphine/Naloxone Taper

This study was undertaken to compare, in an outpatient setting, the relative advantage of two Suboxone® (Bup/Nx) tapering schedules (one rapid and one gradual) following four weeks of Suboxone® stabilization, as reflected by the proportion of participants providing opiate free urines at the end of the taper regimen. In total, 516 participants were randomized to one of two taper schedules, either 7 days or 28 days. The reason for conducting this study was not to advocate for short-term treatment, but to determine the relative ease of using a more rapid vs. a gradual taper should someone need to discontinue Bup/Nx.

CTN Protocol ID: 
CTN-0003
DSMB ID: 
3
Enrollment Status: 
Completed
ClinicalTrials.gov ID: 
Primary Outcomes Article: 

Ling, W., et al. (2009).  Buprenorphine tapering schedule and illicit opioid use.  Addiction 104: 256-265.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150159/

Principal Investigator(s)
Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Available Brochures

    Attention

    Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at

    Looking for Treatment?

    Use the SAMHSA Treatment Locator or 1-800-662-HELP.

    Helpline open during government shutdown

    Featured Publication

    Featured Publication

    Drugs, Brains, and Behavior - The Science of Addiction

    As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.